NCT00269477View on ClinicalTrials.gov

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

PHASE2CompletedINTERVENTIONAL

Enrollment

145

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

December 31, 2007

Conditions

MeningitisMeningococcal Infection

Interventions

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

BIOLOGICAL

Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

0.5 mL, Intramuscular

Trial Locations (8)

18960

Sellersville

23510

Norfolk

30062

Marietta

30322

Atlanta

37660

Kingsport

43205

Columbus

44308

Akron

01801

Woburn

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00269477 - Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® | Biotech Hunter | Biotech Hunter